JP2010507577A5 - - Google Patents

Download PDF

Info

Publication number
JP2010507577A5
JP2010507577A5 JP2009533536A JP2009533536A JP2010507577A5 JP 2010507577 A5 JP2010507577 A5 JP 2010507577A5 JP 2009533536 A JP2009533536 A JP 2009533536A JP 2009533536 A JP2009533536 A JP 2009533536A JP 2010507577 A5 JP2010507577 A5 JP 2010507577A5
Authority
JP
Japan
Prior art keywords
receptor tyrosine
tyrosine kinase
cancer
kinase
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009533536A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010507577A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/081832 external-priority patent/WO2008051805A2/en
Publication of JP2010507577A publication Critical patent/JP2010507577A/ja
Publication of JP2010507577A5 publication Critical patent/JP2010507577A5/ja
Withdrawn legal-status Critical Current

Links

JP2009533536A 2006-10-23 2007-10-18 トリアゾロピリダジンタンパク質キナーゼモジュレーター Withdrawn JP2010507577A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86255206P 2006-10-23 2006-10-23
US87138406P 2006-12-21 2006-12-21
US91375207P 2007-04-24 2007-04-24
US95283307P 2007-07-30 2007-07-30
PCT/US2007/081832 WO2008051805A2 (en) 2006-10-23 2007-10-18 Triazolo-pyridazine protein kinase modulators

Publications (2)

Publication Number Publication Date
JP2010507577A JP2010507577A (ja) 2010-03-11
JP2010507577A5 true JP2010507577A5 (enExample) 2010-12-02

Family

ID=39031065

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009533536A Withdrawn JP2010507577A (ja) 2006-10-23 2007-10-18 トリアゾロピリダジンタンパク質キナーゼモジュレーター

Country Status (16)

Country Link
US (1) US8071581B2 (enExample)
EP (1) EP2081937B1 (enExample)
JP (1) JP2010507577A (enExample)
KR (1) KR101083177B1 (enExample)
AU (1) AU2007309237B2 (enExample)
BR (1) BRPI0717317A2 (enExample)
CA (1) CA2667453A1 (enExample)
DK (1) DK2081937T3 (enExample)
EA (1) EA016527B1 (enExample)
ES (1) ES2393132T3 (enExample)
MX (1) MX2009004060A (enExample)
PE (1) PE20081256A1 (enExample)
PL (1) PL2081937T3 (enExample)
PT (1) PT2081937E (enExample)
TW (1) TW200833692A (enExample)
WO (1) WO2008051805A2 (enExample)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5420395B2 (ja) 2006-04-07 2014-02-19 バーテックス ファーマシューティカルズ インコーポレイテッド Atp結合カセット輸送体の調節剤
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
GEP20125658B (en) 2006-11-22 2012-10-10 Incyte Corp Imidazotriazines and imidazo pyrimidines as kinase inhibitors
PE20091468A1 (es) 2008-02-28 2009-10-22 Novartis Ag DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA
SI2300455T1 (sl) * 2008-05-21 2017-12-29 Incyte Holdings Corporation Soli 2-fluoro-n-metil-4-(7-(kinolin-6-il-metil)-imidazo(1,2-b)1,2,4) triazin-2-il)benzamid in postopki v zvezi z njihovo pripravo
DE102008028905A1 (de) * 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
DE102008038220A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
EP2356116A1 (en) * 2008-11-20 2011-08-17 OSI Pharmaceuticals, Inc. Substituted pyrroloý2,3-b¨-pyridines and-pyrazines
EP2381777A4 (en) * 2008-12-12 2012-08-08 Ariad Pharma Inc AZAINDOL DERIVATIVES AS KINASEHEMMER
DE102008063667A1 (de) * 2008-12-18 2010-07-01 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
DE102008062825A1 (de) 2008-12-23 2010-06-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
WO2010092371A1 (en) * 2009-02-10 2010-08-19 Astrazeneca Ab Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
JP2012519731A (ja) * 2009-03-09 2012-08-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ニコチン受容体およびgabaa受容体のアロステリックモジュレーターとしての置換複素環およびそれらの使用
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
IN2012DN01453A (enExample) 2009-08-20 2015-06-05 Novartis Ag
PT3511330T (pt) * 2009-12-31 2020-12-24 Hutchison Medipharma Ltd Intermediário sintético útil na preparação de inibidores de triazolopiridina c-met
MX2012008898A (es) 2010-02-03 2012-11-06 Incyte Corp Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met.
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RU2569678C2 (ru) 2010-04-22 2015-11-27 Вертекс Фармасьютикалз Инкорпорейтед Способ получения циклоалкилкарбоксамидо-индольных соединений
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
US20130072495A1 (en) 2010-05-14 2013-03-21 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
JP5960688B2 (ja) 2010-05-17 2016-08-02 インコゼン セラピューティクス プライベート リミテッド プロテインキナーゼ調節物質としての新規3,5−二置換−3h−[1,2,3]トリアゾロ[4,5−b]ピリジン化合物
US8513291B2 (en) * 2010-06-01 2013-08-20 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
AR085183A1 (es) 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP2014513724A (ja) 2011-05-16 2014-06-05 オーエスアイ・ファーマシューティカルズ,エルエルシー 融合二環キナーゼ阻害剤
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
EP2760866B1 (en) 2011-09-27 2017-12-13 Genfit Derivatives of 6-substituted triazolopyridazines as rev-erb agonists
KR101869534B1 (ko) * 2012-03-05 2018-06-20 한국화학연구원 신규한 트리아졸로 피리다진 유도체 및 그의 용도
CN104321322A (zh) 2012-03-30 2015-01-28 理森制药股份公司 作为c-met蛋白激酶调节剂的新型3,5-二取代-3h-咪唑并[4,5-b]吡啶和3,5-二取代-3h-[1,2,3]三唑并[4,5-b]吡啶化合物
AU2013290444B2 (en) 2012-07-16 2018-04-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术(太仓)有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
HK1213887A1 (zh) 2012-10-16 2016-07-15 Janssen Pharmaceutica N.V. RORγt的苯基连接的喹啉基调节剂
WO2014062655A1 (en) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt
MY189505A (en) 2012-10-16 2022-02-16 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of roryt
WO2014133526A1 (en) 2013-02-28 2014-09-04 Empire Technology Development Llc Colored pigment particles for electrophoretic displays
US9303043B2 (en) * 2013-03-13 2016-04-05 Greentech, Inc. Process for making benzoxazepin compounds
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
CN105073747B (zh) 2013-03-15 2017-06-06 普莱希科公司 杂环化合物及其应用
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
CA2926339A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of roryt
CA2927182A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Quinolinyl modulators of ror.gamma.t
GB201321745D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2015134854A2 (en) * 2014-03-06 2015-09-11 Oyagen, Inc. Small molecule vif dimerization antagonists as anti-hiv agents and for use as hiv/aids therapeutics
PL3925607T5 (pl) 2014-04-15 2026-06-01 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
CA2957785C (en) 2014-08-11 2023-01-03 Angion Biomedica Corporation Cytochrome p450 inhibitors and uses thereof
CA2970819A1 (en) 2014-12-31 2016-07-07 Angion Biomedica Corp. Methods and agents for treating disease
CA2980460A1 (en) * 2015-04-13 2016-10-20 Five Prime Therapeutics, Inc. Combination therapy for cancer
CR20180109A (es) 2015-07-20 2018-05-03 Genzyme Corp Inhibidores de receptor del factor estimulador de colonias 1 (csf-1r)
US10717735B2 (en) 2017-10-13 2020-07-21 Plexxikon Inc. Solid forms of a compound for modulating kinases
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
CN113861198B (zh) * 2020-06-30 2024-08-02 上海医药集团股份有限公司 咪唑并[4,5-b]吡嗪类化合物、其制备方法及应用
US11530216B2 (en) 2020-12-23 2022-12-20 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (CSF-1R) inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083139A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
US6960584B2 (en) 2001-04-10 2005-11-01 Merck & Co., Inc. Inhibitors of Akt activity
KR100932677B1 (ko) * 2001-08-10 2009-12-22 요코하마 티엘오 가부시키가이샤 열전달 장치
RS55630B1 (sr) * 2005-12-21 2017-06-30 Janssen Pharmaceutica Nv Triazolopiridazini kao modulatori tirozin kinaze
CA2651979A1 (en) * 2006-05-30 2007-12-06 Pfizer Products Inc. Triazolopyridazine derivatives
PE20121506A1 (es) * 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met

Similar Documents

Publication Publication Date Title
JP2010507578A5 (enExample)
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
NZ592477A (en) Pyrazolylaminopyridines as inhibitors of fak
EP1952825A4 (en) NANOMETER-ORIENTED MEDICAMENT FOR THE MAGNETIC THERMOTHERAPY OF MALIGNEN TUMORS
DK1951729T3 (da) Oxygenbundne pyrimidinderivater
CY1119217T1 (el) Ενωση για την αγωγη του καρκινου
NO2017019I1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
AU2009270856A8 (en) Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
AU2003205077A1 (en) Imaging agents and methods of imaging naaladase of psma
IL191832A (en) Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors
UA100684C2 (uk) Похідні бензилу та піридинілу як модулятори сигнального шляху hedgehog
WO2007013950A3 (en) Combination therapy of her expressing tumors
HUE059861T2 (hu) N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra
EA200901611A1 (ru) Производные 2-оксо-3-бензил-бензоксазол-2-она и родственные соединения в качестве ингибиторов мет киназы для лечения опухолей
CL2009000443A1 (es) Compuestos derivados de 3-metil-imidazo-[1,2-b]-piridazina, moduladores de cinasa de tirosina c-met; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento de enfermedades proliferativas como tumores solidos, metastasis, cancer renal, cancer de cabeza y cuello. cancer pulmon.
EP2274437A4 (en) COMPOSITIONS AND METHODS FOR DETECTING EGFR MUTATIONS IN CANCER
EA200901603A1 (ru) Арил-эфирные производные пиридазинона
JP2009527464A5 (enExample)
WO2007117161A1 (en) Substituted ring fused azines and their use in cancer therapy
MX2009006075A (es) Derivados de acetileno y su uso para la union a placas amiloides y su diagnostico por imagenes.
WO2007090022A3 (en) Novel compounds for targeting endothelial cells, compositions containing the same and methods for their use
MX2009011421A (es) Derivados de ftalazina e isoquinolina con actividades moduladoras del receptor de la s1p.
WO2008112290A3 (en) Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
WO2006137009A3 (en) Fluorescent sulfonamide derivatives having carbonic anhydrase inhibiting activity and their use as therapeutic and diagnostic agents
WO2007016352A3 (en) Oral liquid losartan compositions